Related Experiment Video

Updated: Sep 26, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance

Junichi Kurebayashi1

  • 1Department of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701-0192, Japan.

Breast Cancer (Tokyo, Japan)
|May 9, 2003
PubMed

Insights

Estrogen receptor (ER)-alpha changes, not disappearance, drive endocrine resistance in breast cancer. Understanding these molecular and epigenetic shifts is key to developing new therapies for resistant tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • Estrogen receptor (ER)-alpha is crucial in breast cancer development and response to endocrine therapy.
  • A significant portion of breast cancers are resistant to endocrine therapy or develop resistance over time.
  • Current research focuses on understanding the mechanisms behind endocrine resistance to improve treatment outcomes.

Purpose of the Study:

  • To investigate the role of estrogen receptor (ER)-alpha in endocrine-resistant breast cancer.
  • To elucidate the molecular and epigenetic mechanisms contributing to endocrine resistance.
  • To identify potential strategies for overcoming endocrine resistance in breast cancer.

Main Methods:

  • Analysis of quantitative and qualitative changes in ER-alpha in endocrine-resistant breast cancer.
  • Investigation of molecular alterations such as ER-alpha gene mutations and phosphorylation.
  • Exploration of epigenetic factors, including hypoxia, in inducing endocrine resistance.

Main Results:

  • Disappearance of ER-alpha is not a common cause of endocrine resistance; many resistant tumors retain ER-alpha expression.
  • Qualitative and functional changes in ER-alpha, including mutations and phosphorylation, are implicated in resistance.
  • Epigenetic modifications, such as hypoxia, may also contribute to the development of endocrine resistance.

Conclusions:

  • Endocrine resistance in breast cancer is complex and involves alterations in ER-alpha function rather than its absence.
  • Understanding these molecular and epigenetic mechanisms is vital for developing novel therapeutic approaches.
  • Further research into ER-alpha modifications and epigenetic factors can lead to strategies to overcome endocrine resistance.

More Related Videos

Epigenome-Wide CRISPR-Cas9-Based Knockout Screens on Chemoresistant Cells12:25

Epigenome-Wide CRISPR-Cas9-Based Knockout Screens on Chemoresistant Cells

Published on: July 21, 2026

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...